These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19843189)

  • 1. Utilization of (111)In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy.
    Kimura M; Tsivian M; Mouraviev V; Mayes JM; Price MM; Bannister MC; Madden JF; Wong TZ; Polascik TJ
    Int J Urol; 2009 Dec; 16(12):971-5. PubMed ID: 19843189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 111-In-capromab pendetide imaging using hybrid-γ camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer.
    Tsivian M; Wright T; Price M; Mouraviev V; Madden JF; Kimura M; Wong T; Polascik TJ
    Urol Oncol; 2012; 30(2):150-4. PubMed ID: 20189846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.
    Schuster DM; Savir-Baruch B; Nieh PT; Master VA; Halkar RK; Rossi PJ; Lewis MM; Nye JA; Yu W; Bowman FD; Goodman MM
    Radiology; 2011 Jun; 259(3):852-61. PubMed ID: 21493787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
    Raj GV; Partin AW; Polascik TJ
    Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer.
    Rieter WJ; Keane TE; Ahlman MA; Ellis CT; Spicer KM; Gordon LL
    Clin Nucl Med; 2011 Oct; 36(10):872-8. PubMed ID: 21892036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.
    Nagda SN; Mohideen N; Lo SS; Khan U; Dillehay G; Wagner R; Campbell S; Flanigan R
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):834-40. PubMed ID: 17293236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer.
    Hardie AD; Rieter WJ; Bradshaw ML; Gordon LL; Young MA; Keane TE
    World J Urol; 2013 Dec; 31(6):1327-32. PubMed ID: 23595605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capromab Pendetide imaging of prostate cancer.
    Haseman MK; Rosenthal SA; Polascik TJ
    Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.
    Schuster DM; Nieh PT; Jani AB; Amzat R; Bowman FD; Halkar RK; Master VA; Nye JA; Odewole OA; Osunkoya AO; Savir-Baruch B; Alaei-Taleghani P; Goodman MM
    J Urol; 2014 May; 191(5):1446-53. PubMed ID: 24144687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy.
    Thomas CT; Bradshaw PT; Pollock BH; Montie JE; Taylor JM; Thames HD; McLaughlin PW; DeBiose DA; Hussey DH; Wahl RL
    J Clin Oncol; 2003 May; 21(9):1715-21. PubMed ID: 12721246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seminal vesicle invasion on multi-parametric magnetic resonance imaging: Correlation with histopathology.
    Grivas N; Hinnen K; de Jong J; Heemsbergen W; Moonen L; Witteveen T; van der Poel H; Heijmink S
    Eur J Radiol; 2018 Jan; 98():107-112. PubMed ID: 29279147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer.
    Ellis RJ; Kaminsky DA; Zhou EH; Fu P; Chen WD; Brelin A; Faulhaber PF; Bodner D
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):29-34. PubMed ID: 20961696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set co-registration independently predicts biochemical failure.
    Ellis RJ; Zhou EH; Fu P; Kaminsky DA; Sodee DB; Faulhaber PF; Bodner D; Resnick MI
    J Urol; 2008 May; 179(5):1768-73; discussion 1773-4. PubMed ID: 18343445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy.
    Wilkinson S; Chodak G
    J Urol; 2004 Jul; 172(1):133-6. PubMed ID: 15201753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer.
    Schettino CJ; Kramer EL; Noz ME; Taneja S; Padmanabhan P; Lepor H
    AJR Am J Roentgenol; 2004 Aug; 183(2):519-24. PubMed ID: 15269050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indium-111 capromab pendetide in the management of recurrent prostate cancer.
    Manyak MJ
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):175-81. PubMed ID: 18279057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.
    Rosenthal SA; Haseman MK; Polascik TJ
    Tech Urol; 2001 Mar; 7(1):27-37. PubMed ID: 11272670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.
    Koontz BF; Mouraviev V; Johnson JL; Mayes J; Chen SH; Wong TZ; Anscher MS; Sun L; Moul J; Polascik TJ
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):358-61. PubMed ID: 18164863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy.
    Kahn D; Williams RD; Haseman MK; Reed NL; Miller SJ; Gerstbrein J
    J Clin Oncol; 1998 Jan; 16(1):284-9. PubMed ID: 9440754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrasound analysis of seminal vesicles in prostate cancer invasion: monocentric experience of an extended prostate biopsy scheme.
    Dell'Atti L; Galosi AB
    Abdom Radiol (NY); 2017 Apr; 42(4):1250-1254. PubMed ID: 27838771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.